MYOMO (MYO) Company Report

Myomo reported Q3 2025 revenue of $10.1 million, a 10% increase compared to Q3 2024, and reiterated its full-year revenue guidance of $40 million to $42 million.
The company posted a net loss of $3.7 million, or $0.09 per share, for Q3 2025, compared to a net loss of $1.0 million, or $0.03 per share, in Q3 2024.
Operationally, Myomo achieved 229 MyoPro orders in Q3, marking its strongest quarter of the year, and saw a 28% increase in new patient pipeline candidates from Q3 2024.
On November 4, 2025, Myomo entered a new debt financing arrangement, securing $17.5 million in committed term loans, with $12.5 million funded at closing. This resulted in a pro forma cash balance of $20.1 million as of September 30, 2025.
The company is also undertaking manufacturing cost reduction projects anticipated to yield 200 basis points of gross margin improvement beginning in Q3 2026.

Nov 10, 2025, 9:10 PM

8-K

Myomo Reports Q3 2025 Financial and Operating Results

MYO

Earnings

Guidance Update

Debt Issuance

Myomo reported revenue of $10.1 million for the third quarter of 2025, a 10% increase compared to the third quarter of 2024, and reiterated its full-year 2025 revenue guidance of $40 million to $42 million.
The company recorded an operating loss of $3.5 million and a net loss of $3.7 million, or $0.09 per share, for Q3 2025, compared to an operating loss of $1.0 million and a net loss of $1.0 million, or $0.03 per share, in Q3 2024. Gross margin for Q3 2025 was 63.8%, down from 75.4% in the prior year period.
Myomo achieved 229 MyoPro orders and authorizations in Q3 2025, marking its strongest quarter of the year for orders, and added 826 new candidates to its patient pipeline, a 28% increase from Q3 2024.
On November 4, 2025, Myomo entered into a new debt financing arrangement for $17.5 million, with $12.5 million funded at closing, resulting in a pro forma cash balance of $20.1 million as of September 30, 2025, net of debt repayment, fees, and expenses.

Nov 10, 2025, 9:05 PM

Press Release

Myomo outlines Q1 2025 Investor Day Strategic Roadmap & Growth Targets

MYO

Guidance Update

New Projects/Investments

Aims to achieve $100 million in annual revenue by 2028 with a diversified mix—including 20% U.S. O&P (targeting $20 million), 15% international ($15 million), and direct billing—and robust margins (70–72% gross, 15–20% EBITDA). [1,5]
Manufacturing expansion underway with new facility space coming online in July, targeting 250 units/month MyoPro production by 2028. [2,5]
Cost-of-goods reduction projects are expected to deliver approximately 200 basis points of quarterly gross margin improvement by Q4 2026. [2,5]
Strong Q1 financial position with $21.5 million in cash, a $2.7 million burn, an undrawn $4 million line of credit (with $1.9 million available), and a $3 million term loan; breakeven achieved at $17–18 million quarterly revenue. [4,5]
U.S. O&P channel strategy aims to certify ~200 clinicians, each averaging 4 units annually, driving targeted revenue growth. [3,5]
Management reported Q1 2025 lead generation recovery, noting that roughly half of new pipeline additions come from leads over one year old.
Over 27 million lives are covered by private payer contracts, with ongoing efforts to enhance Medicare Advantage reimbursement.

Jun 19, 2025, 5:12 PM

8-K

Myomo Inc Reports Q1 2025 Financial & Operating Results

MYO

Earnings

Revenue Acceleration/Inflection

Product Launch

Guidance Update

Revenue reached $9.8 million, up 162% YoY, driven by strong unit sales (182 MyoPro units) and a 31% increase in ASP to ~$54K; Medicare Part B patients contributed about 60% of revenue .
Gross margin improved to 67.2%, resulting in an operating and net loss of $3.5 million with Adjusted EBITDA of $(2.8) million .
The patient pipeline expanded to nearly 1,500 patients with a record 700 new candidates and 213 MyoPro orders, despite only an 18% rise in authorizations and a 9% decline in the backlog .
New product launches, including the MyoPro 2x and MARK 2 clinical unit, along with an expanded O&P channel (now with over 300 trained clinicians), are set to boost future growth .
Guidance: Q2 revenue is expected to be in the $9.0–$9.5 million range with full-year 2025 revenue guidance of $50–$53 million .

May 7, 2025, 8:31 PM

Transcript 8-K

Myomo Inc Reports Record Q4 2024 Revenue and Operational Improvements

MYO

Earnings

Revenue Acceleration/Inflection

Guidance Update

Record Q4 revenue of $12.1M was achieved, more than doubling Q4 2023 figures, driven by greater Medicare Part B coverage and a record 220 revenue units delivered, with a significant increase in patient pipeline additions.
Operating efficiency improved sharply as the operating loss narrowed to $200K (down from $2.4M in Q4 2023) and the company reached positive adjusted EBITDA of $200K, marking a key milestone in cash flow break-even.
Capacity expansion and strategic investments were highlighted by a move to a new 35,000 sq ft facility in suburban Burlington, enhanced manufacturing capacity of 120 units/month, and the hiring of 100 new staff members, supporting scalability for future growth.
Growth outlook for 2025 is positive, with revenue guidance between $50M and $53M, underpinned by expected momentum from both the direct provider channel and the growing O&P channel, along with an anticipated uplift in average selling prices (ASP).

Mar 10, 2025, 8:31 PM

Transcript

Myomo Announces Q4 2024 Financial Results

MYO

Earnings

Revenue Acceleration/Inflection

Guidance Update

The company achieved $12.1 million in record revenue for Q4 2024, representing a 154% increase year-over-year.
It reported its first-ever positive quarterly cash flow from operations at $3.4 million.
The period also saw a record 233 MyoPro unit authorizations/orders and 657 new additions to the pipeline.
Looking ahead, Myomo provided a revenue guidance of $50–$53 million for 2025.

Mar 10, 2025, 12:00 AM

8-K

Earnings Transcripts

Quarterly earnings call transcripts for MYOMO.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Paul Gudonis say about margins?What are MYOMO's strategic priorities?How is MYOMO positioned vs competitors?How did MYOMO do last quarter?

Let Fintool AI Agent track MYOMO's earnings for you

Get instant analysis when filings drop